TR201819211T4 - Kanserli Hastaların Taranmasına Yönelik Yöntemler Ve Kitler - Google Patents
Kanserli Hastaların Taranmasına Yönelik Yöntemler Ve Kitler Download PDFInfo
- Publication number
- TR201819211T4 TR201819211T4 TR2018/19211T TR201819211T TR201819211T4 TR 201819211 T4 TR201819211 T4 TR 201819211T4 TR 2018/19211 T TR2018/19211 T TR 2018/19211T TR 201819211 T TR201819211 T TR 201819211T TR 201819211 T4 TR201819211 T4 TR 201819211T4
- Authority
- TR
- Turkey
- Prior art keywords
- patient
- genes
- expression level
- eli1
- ela1
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 4
- 201000011510 cancer Diseases 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 3
- 238000012216 screening Methods 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 abstract 3
- 101100166845 Arabidopsis thaliana CESA3 gene Proteins 0.000 abstract 2
- 101100298284 Arabidopsis thaliana ELI1 gene Proteins 0.000 abstract 2
- 102100035371 Chymotrypsin-like elastase family member 1 Human genes 0.000 abstract 2
- 101000737684 Homo sapiens Chymotrypsin-like elastase family member 1 Proteins 0.000 abstract 2
- 230000033289 adaptive immune response Effects 0.000 abstract 2
- 230000001506 immunosuppresive effect Effects 0.000 abstract 2
- 230000004044 response Effects 0.000 abstract 2
- 230000000259 anti-tumor effect Effects 0.000 abstract 1
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 229940127089 cytotoxic agent Drugs 0.000 abstract 1
- 239000002955 immunomodulating agent Substances 0.000 abstract 1
- 230000003439 radiotherapeutic effect Effects 0.000 abstract 1
- 230000004083 survival effect Effects 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/16—Primer sets for multiplex assays
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pathology (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Engineering & Computer Science (AREA)
- Analytical Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
Abstract
(i) bir hastadan ede edilen bir tümör numunesinde, insan adaptif immün yanıtının temsili olan bir veya birden fazla genin (GA1 - GAn) bir ekspresyon seviyesinin (ELA1 - ELAn) ve insan immünosüpresif yanıtının temsili olan bir veya birden fazla genin (Gl1 - GIn) bir ekspresyon seviyesinin (ELI1 - ELIn) bir hastadan elde edilmesini, (ii) i) adımında belirlenen ekspresyon seviyelerinin (ELA1 - ELAn ve ELI1 - ELIn), söz konusu genlerin ekspresyon seviyesine ve Kaplan Meier eğrilerine ve ilişkili log-sıra p değerlerine göre hastaların sağkalımına göre iki gruba, kanser hastalarının bir panelini ayıran söz konusu önceden belirlenmiş referans değerleri gibi seçilen önceden belirlenmiş referans değerleri (ELRA1 - ELRAn ve ELRI1 - ELRIn) ile kıyaslanmasını, iii) hastanın, iyi (önceden belirlenmiş referans değerinden daha yüksek seviye) veya bir kötü (önceden belirlenmiş referans değerinden daha düşük seviye) adaptif immün yanıtına ve iyi veya kötü bir immünosüpresif yanıta sahip olup olmadığı ile sonuçlanmasını içeren kanser hastalarının taranmasına yönelik, ayrıca tercihe bağlı olarak bir hastanın bir antitümöral tedaviyi alıp almayacağı ile sonuçlanması adımını, i) adımının uygulanmasına yönelik bileşenleri ve yönteme göre antitümöral tedaviye yanıt veren olarak bir kanser hastasının tedavisinde kullanıma yönelik bir kemoterapötik maddeyi, bir immünoterapötik maddeyi veya bir radyoterapötik maddeyi içeren bir kiti içeren bir yöntem.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12305975 | 2012-08-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TR201819211T4 true TR201819211T4 (tr) | 2019-01-21 |
Family
ID=46762994
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TR2018/19211T TR201819211T4 (tr) | 2012-08-06 | 2013-08-05 | Kanserli Hastaların Taranmasına Yönelik Yöntemler Ve Kitler |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20150218650A1 (tr) |
| EP (2) | EP3470531A1 (tr) |
| JP (2) | JP6559566B2 (tr) |
| AU (1) | AU2013301609B2 (tr) |
| CA (1) | CA2881389C (tr) |
| DK (1) | DK2880180T3 (tr) |
| ES (1) | ES2702722T3 (tr) |
| LT (1) | LT2880180T (tr) |
| PL (1) | PL2880180T3 (tr) |
| PT (1) | PT2880180T (tr) |
| SG (1) | SG11201500922RA (tr) |
| TR (1) | TR201819211T4 (tr) |
| WO (1) | WO2014023706A1 (tr) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20210060670A (ko) | 2008-12-09 | 2021-05-26 | 제넨테크, 인크. | 항-ｐｄ-ｌ１ 항체 및 ｔ 세포 기능을 향상시키기 위한 그의 용도 |
| SG11201700978SA (en) * | 2014-08-19 | 2017-03-30 | Univ Okayama Nat Univ Corp | Method for enhancing immune cell function and method for assessing immune cell multifunctionality |
| CN107208138A (zh) * | 2014-12-30 | 2017-09-26 | 豪夫迈·罗氏有限公司 | 用于癌症预后和治疗的方法和组合物 |
| EP3455631B1 (en) * | 2016-05-09 | 2020-06-24 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for classifying patients with a solid cancer |
| JP7256127B2 (ja) | 2017-03-01 | 2023-04-11 | ジェネンテック， インコーポレイテッド | がんのための診断及び治療方法 |
| KR102350221B1 (ko) | 2018-03-22 | 2022-01-14 | 스미또모 덴꼬오 하드메탈 가부시끼가이샤 | 표면 피복 절삭 공구 및 그 제조 방법 |
| JP2022536075A (ja) | 2019-06-03 | 2022-08-12 | アンセルム（アンスティチュート・ナシオナル・ドゥ・ラ・サンテ・エ・ドゥ・ラ・ルシェルシュ・メディカル） | 処置レジメンを調節する方法 |
| AU2020378280A1 (en) | 2019-11-07 | 2022-04-07 | Oncxerna Therapeutics, Inc. | Classification of tumor microenvironments |
| GB202007099D0 (en) | 2020-05-14 | 2020-07-01 | Kymab Ltd | Tumour biomarkers for immunotherapy |
| US20230266322A1 (en) | 2020-06-30 | 2023-08-24 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for predicting the risk of recurrence and/or death of patients suffering from a solid cancer after preoperative adjuvant therapy and radical surgery |
| WO2022002873A1 (en) | 2020-06-30 | 2022-01-06 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for predicting the risk of recurrence and/or death of patients suffering from a solid cancer after preoperative adjuvant therapies |
| WO2023175366A1 (en) | 2022-03-17 | 2023-09-21 | Veracyte | Methods for predicting response to an immunotherapeutic treatment in a patient with a cancer |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4888278A (en) | 1985-10-22 | 1989-12-19 | University Of Massachusetts Medical Center | In-situ hybridization to detect nucleic acid sequences in morphologically intact cells |
| US6280929B1 (en) | 1986-01-16 | 2001-08-28 | The Regents Of The University Of California | Method of detecting genetic translocations identified with chromosomal abnormalities |
| US5447841A (en) | 1986-01-16 | 1995-09-05 | The Regents Of The Univ. Of California | Methods for chromosome-specific staining |
| US5427932A (en) | 1991-04-09 | 1995-06-27 | Reagents Of The University Of California | Repeat sequence chromosome specific nucleic acid probes and methods of preparing and using |
| US5472842A (en) | 1993-10-06 | 1995-12-05 | The Regents Of The University Of California | Detection of amplified or deleted chromosomal regions |
| US6942970B2 (en) | 2000-09-14 | 2005-09-13 | Zymed Laboratories, Inc. | Identifying subjects suitable for topoisomerase II inhibitor treatment |
| JP2002363169A (ja) * | 2001-06-08 | 2002-12-18 | Fujiyakuhin Co Ltd | 抗腫瘍活性を有する複素環化合物 |
| WO2005024043A2 (en) * | 2003-09-03 | 2005-03-17 | Government Of The United States Of America, As Represented By Secretary, Department Of Health And Human Services | Methods for identifying, diagnosing, and predicting survival of lymphomas |
| US20110152115A1 (en) * | 2003-09-03 | 2011-06-23 | The United States of America, as represented by the Secretary, Department of Health and | Methods for identifying, diagnosing, and predicting survival of lymphomas |
| EP1893241A2 (en) | 2005-04-28 | 2008-03-05 | Ventana Medical Systems, Inc. | Fluorescent nanoparticles conjugated to antibodies via a peg linker |
| EP3144675A1 (en) | 2005-04-28 | 2017-03-22 | Ventana Medical Systems, Inc. | Enzymes conjugated to antibodies via a peg heterobifuctional linker |
| EP1777523A1 (en) * | 2005-10-19 | 2007-04-25 | INSERM (Institut National de la Santé et de la Recherche Médicale) | An in vitro method for the prognosis of progression of a cancer and of the outcome in a patient and means for performing said method |
| CA2631005C (en) | 2005-11-23 | 2017-02-28 | Ventana Medical Systems, Inc. | Molecular conjugate |
| US20110070582A1 (en) * | 2008-11-03 | 2011-03-24 | Source Precision Medicine, Inc. d/b/d Source MDX | Gene Expression Profiling for Predicting the Response to Immunotherapy and/or the Survivability of Melanoma Subjects |
| ES2816625T3 (es) * | 2010-09-24 | 2021-04-05 | Niels Grabe | Medios y métodos para la predicción de la respuesta a un tratamiento de un paciente con cáncer |
| PL3141617T3 (pl) * | 2011-01-11 | 2019-04-30 | Assist Publique Hopitaux De Paris | Sposoby przewidywania wyniku w związku z nowotworem u pacjenta przez analizowanie ekspresji genów |
-
2013
- 2013-08-05 CA CA2881389A patent/CA2881389C/en active Active
- 2013-08-05 PL PL13745117T patent/PL2880180T3/pl unknown
- 2013-08-05 EP EP18196198.8A patent/EP3470531A1/en not_active Withdrawn
- 2013-08-05 AU AU2013301609A patent/AU2013301609B2/en active Active
- 2013-08-05 PT PT13745117T patent/PT2880180T/pt unknown
- 2013-08-05 TR TR2018/19211T patent/TR201819211T4/tr unknown
- 2013-08-05 WO PCT/EP2013/066425 patent/WO2014023706A1/en active Application Filing
- 2013-08-05 US US14/420,053 patent/US20150218650A1/en not_active Abandoned
- 2013-08-05 ES ES13745117T patent/ES2702722T3/es active Active
- 2013-08-05 DK DK13745117.5T patent/DK2880180T3/en active
- 2013-08-05 JP JP2015525857A patent/JP6559566B2/ja active Active
- 2013-08-05 EP EP13745117.5A patent/EP2880180B1/en active Active
- 2013-08-05 SG SG11201500922RA patent/SG11201500922RA/en unknown
- 2013-08-05 LT LTEP13745117.5T patent/LT2880180T/lt unknown
-
2019
- 2019-07-17 JP JP2019131862A patent/JP6995091B2/ja active Active
-
2020
- 2020-06-09 US US16/896,736 patent/US20200299784A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP2880180A1 (en) | 2015-06-10 |
| PT2880180T (pt) | 2018-12-27 |
| CA2881389C (en) | 2022-01-04 |
| EP3470531A1 (en) | 2019-04-17 |
| ES2702722T3 (es) | 2019-03-05 |
| JP6995091B2 (ja) | 2022-01-14 |
| CA2881389A1 (en) | 2014-02-13 |
| AU2013301609A1 (en) | 2015-02-26 |
| PL2880180T3 (pl) | 2019-04-30 |
| AU2013301609B2 (en) | 2019-03-14 |
| JP6559566B2 (ja) | 2019-08-14 |
| SG11201500922RA (en) | 2015-04-29 |
| EP2880180B1 (en) | 2018-10-03 |
| DK2880180T3 (en) | 2019-01-14 |
| US20200299784A1 (en) | 2020-09-24 |
| US20150218650A1 (en) | 2015-08-06 |
| JP2015530877A (ja) | 2015-10-29 |
| LT2880180T (lt) | 2019-01-25 |
| JP2019176880A (ja) | 2019-10-17 |
| WO2014023706A1 (en) | 2014-02-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TR201819211T4 (tr) | Kanserli Hastaların Taranmasına Yönelik Yöntemler Ve Kitler | |
| MX2023002251A (es) | Antagonistas de union al eje pd-l1 y usos de los mismos para el tratamiento de cancer. | |
| MX2022006075A (es) | Antagonistas de union a pd-l1 y usos de los mismos para el tratamiento de cancer. | |
| JP2015530877A5 (tr) | ||
| RU2015125575A (ru) | Композиции и способы для лечения злокачественной опухоли | |
| PH12017500556A1 (en) | Use of fgfr mutant gene panels in identifying cancer patients that will be responsive to treatment with an fgfr inhibitor | |
| MX2019003934A (es) | Métodos terapéuticos y de diagnóstico para el cáncer. | |
| MX2018010361A (es) | Métodos terapéuticos y de diagnóstico para el cáncer. | |
| EP3839510A3 (en) | Blood-based biomarkers of tumor sensitivity to pd-1 antagonists | |
| MX2023001945A (es) | Composiciones y metodos para el cribado de tumores solidos. | |
| HK1103439A1 (en) | Detection of elevated levels of her-2/neu protein on circulating cancer cells and treatment | |
| WO2018007872A9 (en) | Biomarkers for inflammatory bowel disease | |
| NZ621733A (en) | Lung cancer biomarkers and uses thereof | |
| WO2018183817A3 (en) | Tumor burden as measured by cell free dna | |
| WO2018081625A3 (en) | Digital analysis of blood samples to determine efficacy of cancer therapies for specific cancers | |
| EA202190474A1 (ru) | Терапия на основе микро-рнк, направленная против lcp-1-позитивных раковых опухолей | |
| EA201890649A1 (ru) | Новые биомаркеры и способы лечения рака | |
| EA201690680A1 (ru) | Комбинированное противоопухолевое лечение с применением миниклеток, загруженных лекарственным средством, нацеленных с использованием биспецифического лиганда, и интерферона-гамма | |
| WO2020107002A3 (en) | Methods for expansion of natural killer (nk) cell subset and related compositions and methods | |
| MX2021003214A (es) | Metodos terapeuticos y de diagnostico para el cancer de vejiga. | |
| WO2013106766A3 (en) | THERAPEUTIC INDICATIONS OF miR-1291 | |
| RU2015153810A (ru) | Способ прогнозирования терапевтического эффекта для пациента с колоректальным раком, у которого повышена экспрессия белка tk1 | |
| RU2013119459A (ru) | Комплекс ipp в качестве маркера лечения эрлотинибом | |
| EA201890816A1 (ru) | Вариант 7as андрогенового рецептора как биомаркер для выбора лечения пациентов с метастатическим раком простаты, резистентным к кастрации (mcrpc) | |
| MX2023005604A (es) | Composiciones, dispositivos, y metodos de prueba de sensibilidad para el trastorno de deficit de atencion/trastorno de hiperactividad con deficit de atencion (add/adhd). |